NanoViricides

NNVC

Market cap $23.3M

Overview Fund Activity

1.45 USD

0.00

0%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

1.47

+0.02

1.38%

1 day

0%

5 days

-1.36%

1 month

-3.33%

3 months

0%

6 months

10.69%

Year to date

2.11%

1 year

-3.33%

5 years

-68.13%

10 years

-92.96%

About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Employees: 7

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

7% more capital invested

Capital invested by funds: $1.74M [Q1] → $1.87M (+$130K) [Q2]

1.2% less ownership

Funds ownership: 9.5% [Q1] → 8.3% (-1.2%) [Q2]

11% less funds holding

Funds holding: 37 [Q1] → 33 (-4) [Q2]

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

See Fund Rankings

Financial journalist opinion

Based on 5 articles about NNVC published over the past 30 days

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA.

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA. Event Information: Event NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA Day & Date Wednesday, September 17, 2025 Time 12:30 pm Location LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Proactive Investors

NanoViricides says broad-spectrum antiviral candidate NV-387 could address current, emerging and future COVID strains

NanoViricides (NYSE-A:NNVC) has highlighted the potential of its broad-spectrum antiviral NV-387 to address emerging COVID variants as cases of the new “Stratus” strain climb in California. The Stratus variant, a descendant of Omicron, now accounts for the vast majority of cases detected in wastewater, according to Los Angeles county health officials.

NanoViricides says broad-spectrum antiviral candidate NV-387 could address current, emerging and future COVID strains

Proactive Investors

NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

NanoViricides (NYSE-A:NNVC) said on Monday that its experimental broad-spectrum antiviral drug NV-387, now advancing into Phase II clinical trials, may help lower the risk of metastatic cancer returning in patients following viral infections. The company said recent studies have found that inflammation, particularly elevated levels of the cytokine IL-6 caused by infections such as COVID-19 and influenza, can reactivate dormant cancer cells, leading to the resurgence of metastatic disease.

NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of "sleeping" cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials.

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Proactive Investors

NanoViricides says antiviral candidate NV-387 could address global measles surge

NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nations including the US, Canada, the UK, and the EU. The company said NV-387 has shown safety and effectiveness in preclinical studies using humanized mouse models and has completed a Phase I clinical trial with no reported adverse events, supporting its potential as a measles treatment.

NanoViricides says antiviral candidate NV-387 could address global measles surge

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Proactive Investors

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in global pandemic preparedness. The Connecticut-based biotech firm said its NV-387 compound has demonstrated effectiveness in animal studies against a wide range of viral threats, including MPox, Smallpox, Measles, Influenza, Coronaviruses, and other orthopoxviruses.

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio.

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Proactive Investors

NanoViricides says lead antiviral boosted survival in measles-infected mice

NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based biotech firm reported increased survival in mice infected with a lethal dose of the measles virus by 130%, extending average survival time to 17 days compared to 7.4 days in untreated animals.

NanoViricides says lead antiviral boosted survival in measles-infected mice

See News Rankings

Charts implemented using Lightweight Charts™